Virogates completes cheap and simple prognostic kit for HIV patients  

2006.04.27
Danish biotech company Virogates has completed production of its first batch of suPARnostic kits for the monitoring of HIV disease progression

Danish biotech company Virogates has completed production of its first batch of suPARnostic kits for the monitoring of HIV disease progression. The suPARnostic kit is an inexpensive and simple blood test which can be used to assess when HIV patients will need medical treatment. The invention consists of a small plastic plate onto which a drop of the patient's blood is placed. Shortly afterwards, a colour reaction develops, which shows how close the patient is to developing AIDS.

Testing patients using suPARnostic kits can be carried out on the spot, whereas other tests require extensive laboratory facilities, freezers and patients being close to hospitals. These criteria cannot be met for many HIV infected people in countries such as Africa.

Jesper Eugen-Olsen, chief scientific officer of Virogates says: "We are pleased to report that in collaboration with South African and Norwegian research labs, we have succeeded in identifying a specific permutation demonstrating the strongest clinical relevance, which provides the basis for the now finalized product."

Virogates is preparing the final steps to complete clinical trials which will dictate the kit's usage protocol and complete the registration requirements for CE and IVD approval. suPARnostic is expected to be launched in South Africa in July where it will be sold directly by Virogates' South African subsidiary. Later in the year, ViroGates plans to enter the Indian market, with Brazil and China to follow shortly after. The news was reported in a press release from Virogates.

Link > Virogates 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×